The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Natera acquires Foresight Diagnostics for up to $450M (Medtech Dive)
- $4.2M CDC grant to increase colorectal cancer screening in Pennsylvania (PennState)
- Motility coding changes coming in the new year (AGA)
- Updated Crohn’s Disease Guideline Stresses Early Use of Advanced Drugs (Medscape)
- Check your final 2025 MIPS eligibility (AGA)
- Affordable Care Act subsidies appear likely to expire (Chief Healthcare Executive)
- AI scribes hold ‘transformative potential’ for improving physician burden, patient care (Healio)
- New York Gastroenterology Associates Taps Proscia for Digital Pathology (Bio.IT World)
